Med Ed Report briefs

Orthopedists failed to disclose nearly a third of payments from manufacturers of hip and knee replacements when presenting related research at a recent big meeting, according to a study published in The New England Journal of Medicine. The study gauged the veracity of disclosures by orthopedic surgeons presenting at a 2008 meeting of the American Academy of Orthopaedic Surgeons and found that presenters failed to properly disclose 29% of payments accounting for more than $4 million.

Merck and Schering-Plough spent around $60 million from 2004 to 2008 on CME around cardiovascular topics, according to Dow Jones Newswires. The figures came from the Senate Special Committee on Aging, whose chairman, Sen. Herb Kohl (D-WI), cited them as evidence that “when drug companies fund CME, they see it as money well spent on marketing their latest blockbuster drug.”

Sen. Chuck Grassley (R-IA) wrote NIH acting director Raynard Kingston to prod him to look into ghostwriting by Wyeth and Agency DesignWrite, as alleged in an August New York Times piece. Grassley demanded to know the agency's current policy on ghostwriting with regards to NIH researchers, grantee institutions and primary investigators of NIH grants.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.